{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:37:35Z","timestamp":1793777855316,"version":"4.6.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008730","name":"The Norwegian Cancer Society","doi-asserted-by":"publisher","award":["197837"],"award-info":[{"award-number":["197837"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["309555 ENPERITO"],"award-info":[{"award-number":["309555 ENPERITO"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.nano.2023.102656","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T21:10:41Z","timestamp":1673644241000},"page":"102656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Intraperitoneal administration of cabazitaxel-loaded nanoparticles in peritoneal metastasis models"],"prefix":"10.1016","volume":"48","author":[{"given":"Astrid","family":"Hyldbakk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karianne Giller","family":"Fleten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Snipstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.O.","family":"\u00c5slund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina de Lange","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjersti","family":"Flatmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yrr","family":"M\u00f8rch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.nano.2023.102656_bb0005","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jamcollsurg.2013.12.013","article-title":"Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients","volume":"218","author":"Levine","year":"2014","journal-title":"J Am Coll Surg"},{"issue":"14","key":"10.1016\/j.nano.2023.102656_bb0010","first-page":"1363","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.nano.2023.102656_bb0015","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrclinonc.2009.217","article-title":"Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence","volume":"7","author":"Ceelen","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.nano.2023.102656_bb0020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.addr.2016.07.001","article-title":"Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis - mission possible?","volume":"108","author":"Dakwar","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"10.1016\/j.nano.2023.102656_bb0025","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s11095-009-0031-z","article-title":"Drug delivery systems for intraperitoneal therapy","volume":"27","author":"Bajaj","year":"2010","journal-title":"Pharm Res"},{"key":"10.1016\/j.nano.2023.102656_bb0030","article-title":"Optimization of drug delivery systems for intraperitoneal therapy to extend the residence time of the chemotherapeutic agent. Ti TK, Roncucci L, Aoyagi K, Lien HC, editors","volume":"25","author":"De Smet","year":"2013","journal-title":"Sci World J"},{"key":"10.1016\/j.nano.2023.102656_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121189","article-title":"The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis","volume":"279","author":"Kim","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.nano.2023.102656_bb0040","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.jconrel.2020.11.003","article-title":"Tumor-mesoporous silica nanoparticle interactions following intraperitoneal delivery for targeting peritoneal metastasis","volume":"328","author":"Hargrove","year":"2020","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2023.102656_bb0045","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jconrel.2021.12.004","article-title":"I.P.-injected cationic liposomes are retained and accumulate in peritoneally disseminated tumors","volume":"341","author":"Ando-Matsuoka","year":"2022","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.nano.2023.102656_bb0050","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejso.2019.03.035","article-title":"Pharmacokinetics of the intraperitoneal nanoparticle pegylated liposomal doxorubicin in patients with peritoneal metastases","volume":"47","author":"Sugarbaker","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.nano.2023.102656_bb0055","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.2042-7158.1979.tb13510.x","article-title":"Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties","volume":"31","author":"Couvreur","year":"1979","journal-title":"J Pharm Pharmacol"},{"issue":"5\u20136","key":"10.1016\/j.nano.2023.102656_bb0060","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/1061186X.2019.1588280","article-title":"A journey through the emergence of nanomedicines with poly(alkylcyanoacrylate) based nanoparticles","volume":"27","author":"Vauthier","year":"2019","journal-title":"J Drug Target"},{"issue":"6","key":"10.1016\/j.nano.2023.102656_bb0065","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S2468-1253(19)30040-8","article-title":"Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial","volume":"4","author":"Merle","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.nano.2023.102656_bb0070","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jconrel.2018.11.029","article-title":"Cabazitaxel-loaded poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft","volume":"293","author":"Fusser","year":"2019","journal-title":"J Control Release"},{"issue":"11","key":"10.1016\/j.nano.2023.102656_bb0075","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.ultrasmedbio.2017.06.029","article-title":"Ultrasound improves the delivery and therapeutic effect of nanoparticle-stabilized microbubbles in breast cancer xenografts","volume":"43","author":"Snipstad","year":"2017","journal-title":"Ultrasound Med Biol"},{"issue":"5","key":"10.1016\/j.nano.2023.102656_bb0080","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.ultrasmedbio.2020.12.026","article-title":"Sonopermeation enhances uptake and therapeutic effect of free and encapsulated cabazitaxel","volume":"47","author":"Snipstad","year":"2021","journal-title":"Ultrasound Med Biol"},{"issue":"3","key":"10.1016\/j.nano.2023.102656_bb0085","doi-asserted-by":"crossref","DOI":"10.1088\/1748-605X\/abe396","article-title":"Recent progress in nanoformulations of cabazitaxel","volume":"16","author":"Chen","year":"2021","journal-title":"Biomed Mater"},{"issue":"1","key":"10.1016\/j.nano.2023.102656_bb0090","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7150\/ntno.31479","article-title":"Therapeutic effect of cabazitaxel and blood-brain barrier opening in a patient-derived glioblastoma model","volume":"3","author":"Sulheim","year":"2019","journal-title":"Nanotheranostics"},{"issue":"31","key":"10.1016\/j.nano.2023.102656_bb0095","doi-asserted-by":"crossref","first-page":"11876","DOI":"10.1039\/c2ra21544f","article-title":"Highly lipophilic fluorescent dyes in nano-emulsions: towards bright non-leaking nano-droplets","volume":"2","author":"Klymchenko","year":"2012","journal-title":"RSC Adv"},{"issue":"6","key":"10.1016\/j.nano.2023.102656_bb0100","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/(SICI)1097-0215(19960917)67:6<826::AID-IJC12>3.0.CO;2-#","article-title":"Different effects of interferons, interleukin-1beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells","volume":"67","author":"Marth","year":"1996","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.nano.2023.102656_bb0105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10585-016-9829-3","article-title":"Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases","volume":"34","author":"Fleten","year":"2017","journal-title":"Clin Exp Metastasis"},{"issue":"2","key":"10.1016\/j.nano.2023.102656_bb0110","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"issue":"8","key":"10.1016\/j.nano.2023.102656_bb0115","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.humpath.2009.12.013","article-title":"Exploring the peritoneal surface malignancy phenotype\u2014a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models","volume":"41","author":"Flatmark","year":"2010","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.nano.2023.102656_bb0120","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1476-5381.1968.tb00973.x","article-title":"The abdominal constriction response and its suppression by analgesic drugs in the mouse","volume":"32","author":"Collier","year":"1968","journal-title":"Br J Pharmacol Chemother"},{"issue":"4","key":"10.1016\/j.nano.2023.102656_bb0125","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1158\/1535-7163.MCT-15-0713-T","article-title":"Paclitaxel-loaded polymersomes for enhanced intraperitoneal chemotherapy","volume":"15","author":"Sim\u00f3n-Gracia","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"12 Pt 1","key":"10.1016\/j.nano.2023.102656_bb0130","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.nano.2023.102656_bb0135","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1111\/cas.15321","article-title":"Intraperitoneal administration of nanoparticles containing tocopheryl succinate prevents peritoneal dissemination","volume":"113","author":"Hama","year":"2022","journal-title":"Cancer Sci"},{"issue":"7","key":"10.1016\/j.nano.2023.102656_bb0140","first-page":"865","article-title":"Cabazitaxel-loaded poly(alkyl cyanoacrylate) nanoparticles: toxicity and changes in the proteome of breast, colon and prostate cancer cells","volume":"15","author":"\u00d8verbye","year":"2021","journal-title":"Nanotoxicology"},{"key":"10.1016\/j.nano.2023.102656_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112503","article-title":"Clinical implications of chemotherapeutic agent organ toxicity on perioperative care","volume":"146","author":"Zeien","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.nano.2023.102656_bb0150","doi-asserted-by":"crossref","first-page":"8151","DOI":"10.2147\/IJN.S272529","article-title":"Recent clinical developments of nanomediated drug delivery systems of taxanes for the treatment of cancer","volume":"15","author":"van Eerden","year":"2020","journal-title":"Int J Nanomedicine"},{"issue":"2","key":"10.1016\/j.nano.2023.102656_bb0155","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2217\/nnm.15.166","article-title":"Nanoparticle systems reduce systemic toxicity in cancer treatment","volume":"11","author":"Wang","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.nano.2023.102656_bb0160","article-title":"Identification of novel cyanoacrylate monomers for use in nanoparticle drug delivery systems prepared by miniemulsion polymerisation - a multistep screening approach","volume":"4","author":"Hyldbakk","year":"2022","journal-title":"Int J Pharm X"},{"issue":"6","key":"10.1016\/j.nano.2023.102656_bb0165","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/17435390.2019.1576238","article-title":"Small variations in nanoparticle structure dictate differential cellular stress responses and mode of cell death","volume":"13","author":"Szwed","year":"2019","journal-title":"Nanotoxicology"},{"issue":"11","key":"10.1016\/j.nano.2023.102656_bb0170","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.3390\/ijms18112454","article-title":"Cytotoxicity of poly(alkyl cyanoacrylate) nanoparticles","volume":"18","author":"Sulheim","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nano.2023.102656_bb0180","first-page":"1969","article-title":"A review on taxanes: an important group of anticancer compound obtained from Taxus SP","volume":"11","author":"Sinha","year":"2020","journal-title":"Int J Pharm Sci Res"},{"issue":"11","key":"10.1016\/j.nano.2023.102656_bb0185","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.3390\/cancers12113323","article-title":"Mechanisms of taxane resistance","volume":"12","author":"Maloney","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.nano.2023.102656_bb0190","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s00280-018-3572-1","article-title":"Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein","volume":"81","author":"Duran","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.nano.2023.102656_bb0195","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2147\/DDDT.S64940","article-title":"Preclinical profile of cabazitaxel","volume":"8","author":"Vrignaud","year":"2014","journal-title":"Drug Des Devel Ther"},{"issue":"37","key":"10.1016\/j.nano.2023.102656_bb0200","doi-asserted-by":"crossref","first-page":"61800","DOI":"10.18632\/oncotarget.18694","article-title":"MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer","volume":"8","author":"Andersson","year":"2017","journal-title":"Oncotarget"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963423000072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963423000072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:33:01Z","timestamp":1778617981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963423000072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":39,"alternative-id":["S1549963423000072"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2023.102656","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intraperitoneal administration of cabazitaxel-loaded nanoparticles in peritoneal metastasis models","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2023.102656","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102656"}}